Although not statistically significant, there was a trend for the APA patients harboring CTNNB1 mutations to have larger tumor sizes, higher serum potassium and creatinine levels, which implicate that there could be other factors than just aldosterone alone to affect the underlying etiologies and severity of hypertension among these patients. This evidence concerns the gene CTNNB1 and hypertensive disorder.